Abstract
In vitro testing in toxicology was limited for a long time to testing for possible genotoxic properties of a substance. Cell or tissue culture methods are now used for the early toxicological assessment of new substances within the context of screening tests and for mechanistic investigations. In this respect, in vitro methods represent a valuable adjunct to animal studies, without being able to replace animal studies completely at the present time. New developments in the area of microphysiological systems (MPS) suggest that in specific cases like the development of biologics as pharmaceuticals, where relevant animal models are not available due to the human-specific nature of the biologic, but also for improved mechanistic evaluations, human in vitro models will be required or at least deliver helpful information.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aikawa N (2020) A novel screening test to predict the developmental toxicity of drugs using human induced pluripotent stem cells. J Toxicol Sci 45:187–199
Ainslie GR, Davis M, Ewart L, Lieberman LA, Rowlands DJ, Thorley AJ, Yoder G, Ryan AM (2019) Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective. Lab Chip 19:3152–3161
Baudy AR, Otieno MA, Hewitt P, Gan J, Roth A, Keller D, Sura R, Van Vleet TR, Proctor WR (2020) Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry. Lab Chip 20:215–225
Blinova K, Dang Q, Millard D, Smith G, Pierson J, Guo L, Brock M, Lu HR, Kraushaar U, Zeng H, Shi H, Zhang X, Sawada K, Osada T, Kanda Y, Sekino Y, Pang L, Feaster TK, Kettenhofen R, Stockbridge N, Strauss DG, Gintant G (2018) International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment. Cell Rep 24:3582–3592
CHMP/ICH/752211/2012 (2015) ICH guidance on photosafety evaluation of pharmaceuticals. Adopted 25 Aug 2015
CPMP/ICH/423/02 (2005) The non-clinical evaluation of the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals
CPMP/SWP/398/01 (2002) Note for guidance on photosafety
Fabre K, Berridge B, Proctor WR, Ralston S, Will Y, Baran SW, Yoder G, Van Vleet TR (2020) Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications. Lab Chip 20:1049–1057
Galloway SM (2017) International regulatory requirements for genotoxicity testing for pharmaceuticals used in human medicine, and their impurities and metabolites. Environ Mol Mutagen 58:296–324
Gómez-Lechón MJ, Tolosa L, Conde I, Donato MT (2014) Competency of different cell models to predict human hepatotoxic drugs. Expert Opin Drug Metab Toxicol 10:1553–1568
Jang KJ, Otieno MA, Ronxhi J, Lim HK, Ewart L, Kodella KR, Petropolis DB, Kulkarni G, Rubins JE, Conegliano D, Nawroth J, Simic D, Lam W, Singer M, Barale E, Singh B, Sonee M, Streeter AJ, Manthey C, Jones B, Srivastava A, Andersson LC, Williams D, Park H, Barrile R, Sliz J, Herland A, Haney S, Karalis K, Ingber DE, Hamilton GA (2019) Reproducing human and cross-species drug toxicities using a liver-chip. Sci Transl Med 11(517):eaax5516
Kanda Y, Yamazaki D, Osada T, Yoshinaga T, Sawada K (2018) Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update. J Pharmacol Sci 138:233–239
Khetani SR, Berger DR, Ballinger KR, Davidson MD, Lin C, Ware BR (2015) Microengineered liver tissues for drug testing. J Lab Autom 20:216–250
Kretzschmar K, Clevers H (2016) Organoids: modeling development and the stem cell niche in a dish. Dev Cell 38:590–600
Luz AL, Tokar EJ (2018) Pluripotent stem cells in developmental toxicity testing: a review of methodological advances. Toxicol Sci 165:31–39
Marx U, Akabane T, Andersson TB, Baker E, Beilmann M, Beken S, Brendler-Schwaab S, Cirit M, David R, Dehne EM, Durieux I, Ewart L, Fitzpatrick SC, Frey O, Fuchs F, Griffith LG, Hamilton GA, Hartung T, Hoeng J, Hogberg H, Hughes DJ, Ingber DE, Iskandar A, Kanamori T, Kojima H, Kuehnl J, Leist M, Li B, Loskill P, Mendrick DL, Neumann T, Pallocca G, Rusyn I, Smirnova L, Steger-Hartmann T, Tagle DA, Tonevitsky A, Tsyb S, Trapecar M, Van de Water B, Van den Eijnden-van Raaij J, Vulto P, Watanabe K, Wolf A, Zhou X, Roth A (2020) Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. ALTEX 37(3):365–394
Messner S, Agarkova I, Moritz W, Kelm JM (2013) Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol 87:209–213
Mota C, Camarero-Espinosa S, Baker MB, Wieringa P, Moroni L (2020) Bioprinting: from tissue and organ development to in vitro models. Chem Rev 120(19):10547–10607
Noor N, Shapira A, Edri R, Gal I, Wertheim L, Dvir T (2019) 3D printing of personalized thick and perfusable cardiac patches and hearts. Adv Sci (Weinh) 6:1900344
OECD (2004) Test No. 432: in vitro 3T3 NRU phototoxicity test, OECD guidelines for the testing of 485 chemicals, Section 4. OECD Publishing, Paris
OECD (2019) Test guideline No. 432: in vitro 3T3 NRU phototoxicity test, OECD guidelines for the testing of chemicals, Section 4. OECD Publishing, Paris
Peters MF, Choy AL, Pin C, Leishman DJ, Moisan A, Ewart L, Guzzie-Peck PJ, Sura R, Keller DA, Scott CW, Kolaja KL (2020) Developing in vitro assays to transform gastrointestinal safety assessment: potential for microphysiological systems. Lab Chip 20:1177–1190
Phillips JA, Grandhi TSP, Davis M, Gautier JC, Hariparsad N, Keller D, Sura R, Van Vleet TR (2020) A pharmaceutical industry perspective on microphysiological kidney systems for evaluation of safety for new therapies. Lab Chip 20:468–476
Saleem U, van Meer BJ, Katili PA, Mohd Yusof NAN, Mannhardt I, Garcia AK, Tertoolen L, de Korte T, Vlaming MLH, McGlynn K, Nebel J, Bahinski A, Harris K, Rossman E, Xu X, Burton FL, Smith GL, Clements P, Mummery CL, Eschenhagen T, Hansen A, Denning C (2020) Blinded, multicenter evaluation of drug-induced changes in contractility using human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci 176:103–123
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
von Keutz, E. (2021). Toxicity Testing In Vitro: Regulatory Aspects. In: Reichl, FX., Schwenk, M. (eds) Regulatory Toxicology . Springer, Cham. https://doi.org/10.1007/978-3-030-57499-4_35
Download citation
DOI: https://doi.org/10.1007/978-3-030-57499-4_35
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-57498-7
Online ISBN: 978-3-030-57499-4
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences